Pension and Other Postretirement Benefit Plans

9 Months Ended

Sep. 30, 2011

Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Abstract]

Pension and Other Postretirement Benefit Plans [Text Block]

PENSION AND OTHER POSTRETIREMENT BENEFIT PLANS

	Pension		Other Postretirement
Components of Net Periodic Benefit Expense	2011	2010	2011	2010
Millions
For the Quarter Ended September 30,
Service Cost	$1.9	$1.5	$1.0	$1.2
Interest Cost	6.8	6.6	2.7	2.7
Expected Return on Plan Assets	(8.7)	(8.4)	(2.4)	(2.4)
Amortization of Prior Service Costs	0.1	0.1	(0.4)	—
Amortization of Net Loss	3.1	1.6	2.1	1.2
Amortization of Transition Obligation	—	—	—	0.6
Net Periodic Benefit Expense	$3.2	$1.4	$3.0	$3.3
For the Nine Months Ended September 30,
Service Cost	$5.7	$4.6	$2.9	$3.6
Interest Cost	20.5	19.7	8.1	8.2
Expected Return on Plan Assets	(26.0)	(25.2)	(7.3)	(7.2)
Amortization of Prior Service Costs	0.3	0.3	(1.3)	—
Amortization of Net Loss	9.1	4.9	6.4	3.6
Amortization of Transition Obligation	—	—	0.1	1.8
Net Periodic Benefit Expense	$9.6	$4.3	$8.9	$10.0

Employer Contributions. For the nine months ended September 30, 2011, $6.6 million was contributed to our defined benefit pension plan ($1.5 million for the nine months ended September 30, 2010). For the nine months ended September 30, 2011, $10.9 million was contributed to our other postretirement benefit plan ($12.4 million for the nine months ended September 30, 2010). We expect to contribute an additional $27 million to our defined benefit pension plan in 2011, which will reduce our anticipated 2012 contributions, and we expect to contribute an additional $1 million to our other postretirement benefit plan in 2011.

Accounting and disclosure requirements for the Medicare Prescription Drug, Improvement and Modernization Act of 2003 (Act) provides guidance for employers that sponsor postretirement health care plans that provide prescription drug benefits. We provide postretirement health benefits that include prescription drug benefits, which qualify us for the federal subsidy under the Act. For the nine months ended September 30, 2011, we received $0.2 million in prescription drug reimbursements.